France and Australia double Global Fund contributions:
This article was originally published in Clinica
France and Australia are among the latest countries to answer calls from the Global Fund to Fight AIDS, Malaria and Tuberculosis for the world's wealthier countries to increase their contributions. France has pledged to "significantly increase" its contributions in 2006 rising to Euro300m (US$376m) by 2007 - thereby doubling the amount it contributed in each of 2004 and 2005. Australia too has pledged to double its commitment, allocating a further Aus$50m (US$39m) over three years. The pledges come ahead of last week's so-called replenishment conference in Rome. The event will seek to drum up international support for the organisation in the run-up to a final conference in London in September 2005, as it faces challenging funding targets. Current commitments stand at US$2.3bn in 2005, US$3.5bn in 2006 and US$3.6bn in 2007.
You may also be interested in...
Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.